Erectile dysfunction (ED) is the inability to achieve and maintain an erection. Erectile function is dependent upon complex interactions of neural and vascular pathways. A major neurotransmitter that facilitates erectile function is nitric oxide. Treatment of ED has expanded to include effective oral agents. Previous ED treatments have consisted of intracavernosal injection, transurethral dilators, and vascular constriction devices. Clinical management of ED will be presented with some discussion on the prostatectomy client.
Anderson, K.E., & Wagner, G. (1995). Physiology of penile erection. Physiology, 75, 191-236.
2.
Ballard, S.A., Gingell, C.J., Tang, K., Turner, L.A., Price, M.E., & Naylor, A.M. (1998). Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isoenzymes. Journal ofUrology, 159, 2164-2171.
3.
Blackard, C.E., Borken, W.D., Lima, J.S., Nelson J. (1996). Use of vacuum tumescence device for impotence secondary to venous leakage. Urology, 41, 225-227.
4.
Brindley, G.S. (1986). Pilot experiments on the action of drugs injected into the human corpus cavernosum penis. BritishJournal of Pharmacology, 87, 405-500.
5.
Carson, C.C., Rajfer, J., Eardley, I., Carrier, S., Denne, J.S., Walker, D.J., et al. (2004). The efficacy and safety of tadalafil: an update. British Journal of Urology International, 93, 1276-1281.
6.
Cavalini, G. (1991). Minidoxil versus nitroglycerine: Prospective double blind control trial in transcutaneous erection facilitation for organic impotence. Journal ofUrology, 146, 50-53.
7.
Cavalini, G. (1994). Minidoxil and capsacin: An association of transcutaneous active drugs for erection facilitation. International Journal of Impotence Research, 6, D71.
8.
Cookson, M.S., & Nadig, P.W. (1993). Long term results with vacuum constriction device. Journal ofUrology, 149, 290-294.
9.
Costabile, R.A., Spevak, M., Fisherman, I.J., Govier, F.E., Hellstrom, W.J., Shabsigh, R., et al. (1998). Efficacy and Safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy. Journal ofUrology, 157(4), 1424.
10.
Dimitrios, H., Konstantinos, H., Michael, B., Hatzichristou, D., Hatzimouratidis, K., Bekas, M., et al. (2002). Diagnostic steps in the evaluation of patients with erectile dysfunction. Journal ofUrology, 168(2), 615-620.
11.
Dutta, T.C., & Eid, J.F. (1999). Vacuum constriction devices for erectile dysfunction: A long-term, prospective study of patients with mild, moderate, and severe dysfunction. Urology, 54(5), 891-893.
12.
Evans, C. (1999). Complications of intracavernosal therapy for impotence . In C. Carson, R. Kirby, & I. Goldstein (Eds.), Textbook of erectile dysfunction (pp. 365-370). Oxford, UK: Isis Medical Media.
13.
Fraiman, M.C., Lepor, H., & McCullough, A.R. (1999a). Changes in penile morphometrics in men with erectile dysfunction after nerve-sparing radical prostatectomy. MolecularUrology, 3, 109-115.
14.
Fraiman, M.C., Lepor, H., & McCullough, A.R. (1999b). Nocturnal penile tumescence activity in 81 patients presenting with erectile dysfunction after nerve sparing radical prostatectomy. Journal ofUrology, 161, 179.
15.
Fraiman, M.C., Lepor, H., & McCullough, A.R. (2000). Predictive value of nocturnal penile tumescence (NPT) on long term return of erectile function in men with erectile dysfunction (ED) after nerve sparing radical prostatectomy (NSRRP). Journal ofUrology, 163, 242.
16.
Fraiman, M.C., Lepor, H., Telegrafi, S. (2000, September 15). Does early treatment of erectile dysfunction after nerve sparing radical prostatectomy lead to better long term return of natural function? [Abstract]. Paper presented at the Society for the Study of Impotence Meeting, Cleveland, OH.
17.
Goldstein, I., Lue, T.F., Padma-Nathan, H., Rosen, R.C., Steers, W.D., & Wicker, P.A. (1998). For the Sildenafil Study Group: Oral sildenafil in the treatment of erectile dysfunction. New England Journal of Medicine, 338, 1397-1404.
18.
Gould, J.E., Switters, D.M., Broberick, G.A., & deVere White, R.W. (1992). External vacuum devices: A clinical comparison with pharmacologic erections. World Journal of Urology, 10, 68-70.
19.
Heaton, J.P.W., Morales, A., Owen, J., Saunders, F.W., & Fenemore J. (1990). Topical glycerylternitate causes penile arterial diltation in impotent man. Journal ofUrology, 43, 729-731.
20.
Holmquist, F., Anderson, K.E., Fovaeus, M.N., & Hedlund, H. (1990). Potassium channel openers for relaxation of isolated erectile tissue from rabbit. Journal ofUrology, 144, 146-151.
21.
Iwanga, T., Hanyu, S., & Tamaki, M. (1992). VIP and other bioactive substance involved in penile erection. Biological Medicine Research, 2, 71-73.
22.
Jarow, J.P., Burnett, A.L., & Geringer, A.M. (1999). Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment. Journal ofUrology, 162, 722-725.
23.
Kerfoot, W.W., Schwartz, L.B., Hagen, P.O., & Carson, C.C. (1991). Characterization of contracting and relaxing agents in human and rabbit corpus cavernosum. Surgical Forum, 42, 688-689.
24.
Khan, M.A., Thompson, C.S., Sullivan, M.E., Jeremy, J.Y., Mikhailidis, D.P., & Morgan, R.J. (1999). The role of prostaglandins in the etiology and treatment of erectile dysfunction. Prostaglandin Leukot Essent Fatty Acids, 60, 169-174.
25.
Kim, S.C., & Ooh, M.M. (1992). Norepinephrine involvement in response to intracorporeal injection of papaverine in psychogenic impotence. Journal ofUrology, 147, 1530-1532.
26.
Kim, Y.C., Kim, J.A., Hagan, P.O., & Carson, C.C. (1995). Modulation of vasoactive intestinal peptide (VIP) mediated relaxation by nitric oxide and prostenoids in the rabbit corpous cavernosum. Journal ofUrology, 153, 807-810.
27.
Lakin, M.M., Montague, D.K., VanderBrug Medendorp, S., Tesar, L., & Schover, L.R. (1990). Prostaglandin E1 injection therapy for post-prostatectomy impotence: an outcome analysis. Journal of Urology, 155, 639.
28.
McVary, K.T., Polepalle, S., Riggi, S., & Pelham, R.W. (1999). Topical prostaglandin E1 SEPA gel for treatment of erectile dysfunction. Journal of Urology, 162, 726-731.
29.
McMahon, R. (1996). A pilot study for the role of intracavernosal injection of vasoactive intestinal polypeptide (VIP) and phentolamine mesylate in the treatment of erectile dysfunction. International Journal of Impotence Research, 8, 233-236.
30.
Montorsi, F., Guazzoni, G., Strambi, L.F., Da Pozzo, L.F., Nava, L., Barbieri, L., et al. (1996). Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: Results of a prospective, randomized trial. Journal ofUrology, 155, 639.
31.
Montorsi, F., Nathan, H.P., McCullough, A., Brock, G.B., Broderick, G., Ahuja, S., et al. (2004). Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: A randomized, double-blind, placebo controlled trial. Journal ofUrology, 172, 1036-1041.
32.
Montorsi, R., Maga, T., Salonia, A. (2000). Sildenafil taken at bedtime significantly increases nocturnal erectile activity: Results of a prospective Rigiscan study. Journal ofUrology, 164, 148.
33.
Morales, A., Gingell, C., Collins, M., Wicker, P.A., & Osterloh, I.H. (1998). Clinical safety of oral sildenafil citrate (Viagra) in the treatment of erectile dysfunction. International Journal of Impotence Research, 10, 69-74.
34.
Moreland, R.B., Goldstein, I., & Traish, A. (1998). Sildenafil: A novel inhibitor of phoshodiesterase type 5 in human corpus cavernosum smooth muscle cells. Life Sciences, 62, 309-318.
35.
Moreland, R.B., Traish, A., McMillin, M.A., Smith, B., Goldstein, I., & Saenz de Tejada, I. (1995). PGE1 suppresses the induction of collagen synthesis by transforming growth factor beta 1 in human corpus cavernosum smooth muscle. Journal of Urology, 153, 811-815.
36.
Mulhall, J.P., Jahoda, A.E., Cairney, M., Goldstein, B., Leitzes, R., Woods, J., et al. (1999). The causes of patient dropout from penile self-injection therapy for impotence. Journal ofUrology, 162, 1291-1294.
37.
Nehra, A., Blute, M.L., Barrett, D.M., Moreland, R.B. (2002). Rationale for combination therapy of intraurethral prostaglandin E1 and sildenafil in the salvage of erectile dysfunction patients desiring noninvasive therapy. International Journal of Impotence Research, Suppl 1: S38-42.
38.
National Institutes of Health Consensus Conference: Impotence. (1993). Journal of the American Medical Association , 270, 83-90.
39.
Nunez, B.D., & Anderson, D.C. (1993). Nitroglycerine ointment in the treatment of impotence. Journal ofUrology, 150, 1241-1243.
40.
Padma-Nathan, H. (1997). Minimally invasive therapy for erectile dysfunction: Intracavernosal, oral, transdermal/ transglandular and intraurethral approaches . In J. J. Mulcahy (Ed.), Diagnosis and management of male sexual dysfunction (pp. 182-195). New York: Igaku-Shoin.
41.
Padma-Nathan, H., Hellstrom, W.J., Kaiser, F.E., Labasky, R.F., Lue, T.F., Nolten, W.E., et al. (1997). Treatment of men with erectile dysfunction with transurethral alprostadil. New England Journal of Medicine , 336, 1-7.
42.
Paolone, D.R., Lakin, M.M., Ingleright, B.J. (1998, October). Intraurethral alprostadil therapy at The Cleveland Clinic Foundation. North Central Section American Urological Association [Abstract].
43.
Porst, H. (1997). Transurethral alprostadil with MUSE versus intracavernous alprostadil: A comparative study in 103 patients with erectile dysfunction . International Journal of Impotence Research, 9, 187-192.
44.
Purvis, K., Egdetveit, I., & Christiansen, E. (1999). Intracavernosal therapy for erectile failure—Impact of treatment and reasons for dropout and dissatisfaction. International Journal of Impotence Research , 11, 287-299.
45.
Raijfer, J., Aronson, W.J., Bush, P.A., Dorey, F.J., & Ignarry, L.J. (1992). Nitic oxide as a mediator of the corpus cavernosum in response to non cholenergic non adrenergic neurotransmission. New England Journal of Medicine, 326, 90-94.
46.
Raina, R., Agarwal, A., Ausmundson, S., Mansour, D., Zippe, C.D. (2005). Long-term efficacy and compliance of MUSE for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis . International Journal of Impotence Research, 17(1), 86-90.
47.
Raina, R., Agarwal, A., & Zippe, C.D. (2002). Long term efficacy and compliance of sildenafil citrate for ED following radical prostatectomy: 3 year update. Paper presented at the 97th Annual Meeting of the American Urological Association.
48.
Raina, R., Klepacz, H., Agarwal, A., & Zippe, C.D. (2002). Early use of vacuum constriction device (VCD) following radical prostatectomy (RP) facilitates early sexual activity and potential return of erection. Journal ofUrology, 167(4), 1-425.
49.
Raina, R., Lakin, M.M., Agarwal, A., Ausmundson, S., Montague, D.K., & Zippe, C.D. (2004). Long term intracavernous (IC) therapy responders can potentially switch to sildenafil citrate after radical prostatectomy. Urology, 63(3), 532-537.
50.
Rosen, R.C., Riley, A., Wagner, G., Osterloh, I.H., Kirkpatrick, J., & Mishra, A. (1997). The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology, 49, 822-830.
51.
Sadovsky, R., Miller, T., Moskowitz, M., & Hackett, G. (2001). Three year update of sildenafil citrate (Viagra) efficacy and safety. International Journal of Clinical Practice , 55(2), 115-128.
52.
Sidi, A.A., Becher, E.F., Zhang, G., & Lewis, J.H. (1990). Patient acceptance of and satisfaction with an external negative pressure device for impotence. Journal ofUrology, 144, 1154.
53.
Soderdahl, D.W., Thrasher, J.B., & Hansberry, K.L. (1997). Intracavernosal drug-induced erection therapy versus external vacuum devices in the treatment of erectile dysfunction. British Journal of Urology, 79, 952-957.
54.
Stakl, W., Hasun, R., & Marberger, N. (1990). Prostaglandin E-1 in the treatment of erectile dysfunction. World Journal ofUrology, 8, 84-86.
55.
Turner, L.A., Althof, S.E., Levine, S.B., Border, D.R., Kursh, E.D., & Resnik, M.I. (1992). Twelve-month comparison of two treatments for erectile dysfunction: Self-injection versus external vacuum devices. Urology, 39(2), 139-144.
56.
Wiles, P.G. (1988). Successful non-invasive management of erectile impotence in diabetic men. British Medical Journal (Clin Res Ed), 296, 161-162.
57.
Zagaja, G.P., Mhoon, D.A., Aikens, J.E., & Brendler, C.B. (2000). Sildenafil in the treatment of erectile dysfunction after radical prostatectomy. Urology , 56(4), 631-634.
58.
Zippe, C.D., Jhaveri, F.M., Klein, E.A., Kedia, S., Pasqualotto, F.F., Kedia, A., et al. (2000). Role of Viagra after radical prostatectomy . Urology, 55(2), 241-245.
59.
Zippe, C.D., Kedia, A.W., Kedia, K., Nelson, D.R., & Agarwal, A. (1998). Treatment of erectile dysfunction after radical prostatectomy with sildenafil citrate (Viagra). Urology, 52(6), 963-966.
Zippe, C.D., Raina, R., Thukral, M., Lakin, M.M., Klein, E.A., & Agarwal, A. (2001). Management of erectile dysfunction following radical prostatectomy. Current Urology Reports, 2(6), 495-503.
